Background. Bariatric surgery is a choice for treatment in morbidly obese patients with type 2 diabetes mellitus (DM type 2) who have inadequate diabetes control with only medical treatment. However, bariatric surgery requires highly sophisticated equipment, and thus the cost of surgery seems to be very high following the procedure compared with the cost of conventional diabetes care. This raises the question of whether bariatric surgery is cost-effective for morbidly obese people with diabetes in Thailand. Objective. To perform a cost-effectiveness evaluation of bariatric surgery compared with ordinary treatment for diabetes control in morbidly obese DM type 2 patients in Thailand. Methods. Cost-effectiveness study was conducted, using a combination of decision tree and Markov model in analysis. Treatment outcomes and healthcare costs were incurred by data from literature review and retrospective cohort in King Chulalongkorn Memorial Hospital from September 2009 to March 2016 for the conventional and bariatric surgery group, respectively. One-way sensitivity was used for analysis of the robustness of the model. Cost-effectiveness was assessed by calculating incremental cost-effectiveness ratios (ICERs). Monetary benefits at a threshold of 150,000 to 200,000 Thai baht (THB) per quality-adjusted life-year (QALY) based on the Thailand gross domestic products (GDP) value was regarded as cost-effectiveness of bariatric surgery. Results. Bariatric surgery significantly improves the clinical outcome including long-term diabetes remission rate, hemoglobin A1C, and body mass index (BMI). The incremental cost per QALY of bariatric surgery compared with the medication control is 26,907.76 THB/QALY which can consider bariatric surgery as a cost-effective option. Conclusions. Use of bariatric surgery in morbidly obese with DM type 2 patients is a cost-effective strategy in Thailand’s context.
Objectives International guidelines for prostate cancer screening vary, reflecting differences in healthcare systems, population risk profiles, and clinical practice preferences. A key difference among existing prostate cancer screening strategies is the frequency of screening; however, direct comparative evidence between different screening schemes remains limited. This study aimed to compare the effects of various prostate cancer screening intervals on clinical outcomes. Methods This systematic review and meta-analysis included major randomized controlled trials comparing prostate cancer screening methods with no screening. A meta-analysis was conducted to synthesize clinical evidence across various screening strategies. Sensitivity analyses were performed to assess the robustness of findings based on study quality. (PROSPERO ID: CRD42021265092), Results Seven studies evaluating four main prostate cancer screening strategies were included in the meta-analysis. These strategies were categorized into four groups: 1) Two-year screening (e.g., Göteborg), 2) Four-year screening (e.g., ERSPC, Finnish), 3) Short-term screening (e.g., PLCO, Norrköping), and 4) One-time screening (e.g., CAP, Stockholm). In terms of prostate cancer detection, two-year interval screening showed the highest detection rate (RR = 1.88; 95% CI: 1.74–2.02), followed by four-year interval screening (RR = 1.42; 95% CI: 1.26–1.59). The overall analysis showed a significant increase in detection across all strategies (RR = 1.49; 95% CI 1.37–1.62). For prostate cancer-specific mortality, significant reductions were observed with two-year (RR = 0.54; 95% CI: 0.40–0.75) and four-year screening intervals (RR = 0.75; 95% CI: 0.63–0.90). Short-term and one-time screening strategies showed no statistically significant effect yielding an RR of 0.86 (95% CI: 0.73–1.02). Conclusion Based on the meta-analysis results, PSA screening conducted every two to four years appears to offer greater benefits, as both strategies significantly increase prostate cancer detection rates and reduce prostate cancer-related mortality. These findings may support decision making in countries where the optimal PSA screening strategy remains unclear. However, other factors such as targeted age range, cost effective and budget impact analysis should also be considered in the policy decision process.